

# Quang-De Nguyen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6723004/publications.pdf>

Version: 2024-02-01

59  
papers

4,899  
citations

126907

33  
h-index

138484

58  
g-index

60  
all docs

60  
docs citations

60  
times ranked

8662  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Anti-CAIX BBÎ CAR4/8 TÂcells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.  | 4.4  | 15        |
| 2  | Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. <i>Cancer Research</i> , 2022, 82, 248-263.   | 0.9  | 17        |
| 3  | Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.   | 7.0  | 100       |
| 4  | DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i12-i13.   | 0.7  | 1         |
| 5  | FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. <i>Nature Cell Biology</i> , 2021, 23, 1187-1198.                               | 10.3 | 21        |
| 6  | Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , 2020, 78, 1096-1113.e8.   | 9.7  | 114       |
| 7  | IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii106-ii106.  | 1.2  | 1         |
| 8  | TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE. <i>Neuro-Oncology</i> , 2020, 22, ii230-ii231.  | 1.2  | 1         |
| 9  | An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.  | 28.9 | 1,408     |
| 10 | Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. <i>Cancer Cell</i> , 2019, 36, 528-544.e10.   | 16.8 | 128       |
| 11 | The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. <i>Genes and Development</i> , 2019, 33, 1718-1738. | 5.9  | 65        |
| 12 | Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. <i>Nature Communications</i> , 2019, 10, 4182.   | 12.8 | 37        |
| 13 | Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. <i>Cancer Discovery</i> , 2019, 9, 944-961.   | 9.4  | 36        |
| 14 | Development and Evaluation of an <sup>18</sup> F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression. <i>Molecular Pharmaceutics</i> , 2019, 16, 2106-2117.                                      | 4.6  | 26        |
| 15 | Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. <i>Nanoscale</i> , 2019, 11, 20485-20496.                                | 5.6  | 27        |
| 16 | Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. <i>Cancer Discovery</i> , 2019, 9, 230-247.   | 9.4  | 119       |
| 17 | Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. <i>Cancer Immunology Research</i> , 2018, 6, 389-401.   | 3.4  | 68        |
| 18 | Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.  | 12.6 | 461       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3741-E3748.                                     | 7.1  | 10        |
| 20 | Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model. <i>PLoS ONE</i> , 2018, 13, e0200611.  | 2.5  | 4         |
| 21 | Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using <sup>18</sup> F-ICMT-11 and <sup>18</sup> F-FLT PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1558-1565. | 5.0  | 8         |
| 22 | Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C. <i>Journal of Clinical Investigation</i> , 2017, 127, 4554-4568.   | 8.2  | 21        |
| 23 | Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. <i>PLoS ONE</i> , 2016, 11, e0161427.   | 2.5  | 2         |
| 24 | Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.                                     | 30.7 | 105       |
| 25 | Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. <i>Journal of the American College of Radiology</i> , 2016, 13, 365-371.   | 1.8  | 12        |
| 26 | ImmunopET compared with conventional imaging modalities for the detection of Ewing sarcoma metastases in a preclinical model. <i>Journal of Clinical Oncology</i> , 2015, 33, 10048-10048.   | 1.6  | 0         |
| 27 | Positron Emission Tomography Imaging with <sup>18</sup> F-Labeled Z <sup>HER2:2891</sup> Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies. <i>Clinical Cancer Research</i> , 2014, 20, 1632-1643.       | 7.0  | 32        |
| 28 | Synthesis of a new fluorine- <sup>18</sup> glycosylated "click" cyanoquinoline for the imaging of epidermal growth factor receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 92-96.                                       | 1.0  | 8         |
| 29 | A Novel Radiotracer to Image Glycogen Metabolism in Tumors by Positron Emission Tomography. <i>Cancer Research</i> , 2014, 74, 1319-1328.  | 0.9  | 38        |
| 30 | Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 455-462.   | 2.5  | 22        |
| 31 | Preclinical evaluation of a CXCR4-specific <sup>68</sup> Ga-labelled TN14003 derivative for cancer PET imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 796-803.   | 3.0  | 22        |
| 32 | Preclinical Evaluation of <sup>18</sup> F-Fluoro-2,2-Dimethylpropionic Acid as an Imaging Agent for Tumor Detection. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1506-1512.   | 5.0  | 22        |
| 33 | CXCR4-Targeted and MMP-Responsive Iron Oxide Nanoparticles for Enhanced Magnetic Resonance Imaging. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 9550-9554.  | 13.8 | 146       |
| 34 | Phosphorylation Status of Thymidine Kinase 1 Following Antiproliferative Drug Treatment Mediates <sup>3</sup> -Deoxy- <sup>3</sup> -[ <sup>18</sup> F]-Fluorothymidine Cellular Retention. <i>PLoS ONE</i> , 2014, 9, e101366.                             | 2.5  | 4         |
| 35 | Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3 Selective Molecular Imaging. <i>Clinical Cancer Research</i> , 2013, 19, 3914-3924.  | 7.0  | 48        |
| 36 | Heterogeneity in Lung <sup>18</sup> F-FDG Uptake in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 1214-1224.  | 1.6  | 107       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Scavenging strategy for specific activity improvement: application to a new CXCR4-specific cyclopentapeptide positron emission tomography tracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 679-685.                                    | 1.0 | 9         |
| 38 | Evaluation of Deuterated 18F- and 11C-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2012, 18, 1063-1072.  | 7.0 | 58        |
| 39 | Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. <i>Nuclear Medicine and Biology</i> , 2012, 39, 652-665.   | 0.6 | 16        |
| 40 | 18F-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4. <i>Journal of Fluorine Chemistry</i> , 2012, 135, 200-206.  | 1.7 | 12        |
| 41 | Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells. <i>Translational Oncology</i> , 2011, 4, 241-248.   | 3.7 | 21        |
| 42 | Radiosynthesis and pre-clinical evaluation of [18F]fluoro-[1,2-2H4]choline. <i>Nuclear Medicine and Biology</i> , 2011, 38, 39-51.  | 0.6 | 37        |
| 43 | Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6634-6645.                              | 3.0 | 49        |
| 44 | [18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography. <i>Cancer Research</i> , 2009, 69, 7721-7728.  | 0.9 | 37        |
| 45 | Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [ <sup>18</sup> F]-labeled isatin sulfonamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16375-16380.        | 7.1 | 157       |
| 46 | Design, Synthesis, and Biological Characterization of a Caspase 3/7 Selective Isatin Labeled with 2-[ <sup>18</sup> F]fluoroethylazide. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 8057-8067.  | 6.4 | 126       |
| 47 | Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3112-3121.  | 4.1 | 43        |
| 48 | Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3147-3157.  | 4.1 | 65        |
| 49 | Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G $\alpha$ /G $\beta$ $\gamma$ Protein Complex. <i>Cancer Research</i> , 2006, 66, 9227-9234.   | 0.9 | 57        |
| 50 | Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2070-2077. | 4.1 | 41        |
| 51 | Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. <i>Oncogene</i> , 2005, 24, 8240-8251.   | 5.9 | 47        |
| 52 | Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac. <i>FASEB Journal</i> , 2004, 18, 1016-1018.  | 0.5 | 348       |
| 53 | Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. <i>Cellular Signalling</i> , 2004, 16, 1085-1104.  | 3.6 | 141       |
| 54 | Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. <i>Oncogene</i> , 2003, 22, 4488-4497.                                | 5.9 | 53        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase <sup>2</sup> and EGF receptor signaling. <i>FASEB Journal</i> , 2003, 17, 7-16.   | 0.5 | 117       |
| 56 | RhoA <sup>1</sup> and RhoD <sup>1</sup> dependent regulatory switch of G <sub>i</sub> subunit signaling by PAR <sup>1</sup> receptors in cellular invasion. <i>FASEB Journal</i> , 2002, 16, 565-576.   | 0.5 | 56        |
| 57 | G-protein $\beta$ subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. <i>Oncogene</i> , 2002, 21, 4020-4031.   | 5.9 | 40        |
| 58 | Suppression of Cellular Invasion by Activated G-Protein Subunits G <sub>12o</sub> , G <sub>12i1</sub> , G <sub>12i2</sub> , and G <sub>12i3</sub> and Sequestration of G <sub>12i3</sub> . <i>Molecular Pharmacology</i> , 2001, 60, 363-372. | 2.3 | 41        |
| 59 | Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase <sup>1</sup> and thromboxane A2 receptor <sup>1</sup> dependent signaling pathways. <i>FASEB Journal</i> , 2001, 15, 1517-1528.                     | 0.5 | 72        |